Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment
Open Access
- 1 January 2023
- journal article
- review article
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 45 (2) , 1-60
Abstract
Objectives: To summarize evidence-based pharmacological treatments and provide guidance on clinical interventions for adult patients with obsessive-compulsive disorder (OCD).Methods: The American Psychiatric Association (APA) guidelines for the treatment of OCD (2013) were updated with a systematic review assessing the efficacy of pharmacological treatments for adult OCD, comprising monotherapy with selective serotonin reuptake inhibitors (SSRIs), clomipramine, serotonin and norepinephrine reuptake inhibitors (SNRIs), and augmentation strategies with clomipramine, antipsychotics, and glutamate-modulating agents. We searched for the literature published from 2013-2020 in five databases, considering the design of the study, primary outcome measures, types of publication, and language. Selected articles had their quality assessed with validated tools. Treatment recommendations were classified according to levels of evidence developed by the American College of Cardiology and the American Heart Association (ACC/AHA). Results: We examined 57 new studies to update the 2013 APA guidelines. High-quality evidence supports SSRIs for first-line pharmacological treatment of OCD. Moreover, augmentation of SSRIs with antipsychotics (risperidone, aripiprazole) is the most evidence-based pharmacological interven-tion for SSRI-resistant OCD. Conclusion: SSRIs, in the highest recommended or tolerable doses for 8-12 weeks, remain the first -line treatment for adult OCD. Optimal augmentation strategies for SSRI-resistant OCD include low doses of risperidone or aripiprazole. Pharmacological treatments considered ineffective or potentially harmful, such as monotherapy with antipsychotics or augmentation with ketamine, lamotrigine, or N-acetylcysteine, have also been detailed.Keywords
This publication has 91 references indexed in Scilit:
- Pharmacotherapy of obsessive-compulsive disorder: Evidence-based treatment and beyondAustralian & New Zealand Journal of Psychiatry, 2012
- EFFECTS OF ARIPIPRAZOLE AUGMENTATION IN TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER (A DOUBLE BLIND CLINICAL TRIAL)Depression and Anxiety, 2012
- Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive–compulsive disorderInternational Clinical Psychopharmacology, 2009
- Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorderMolecular Psychiatry, 2009
- Emotional burden in caregivers of patients with obsessive-compulsive disorderDepression and Anxiety, 2008
- The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey ReplicationMolecular Psychiatry, 2008
- Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)Cochrane Database of Systematic Reviews, 2008
- Augmentation of Serotonin Reuptake Inhibitors in Refractory Obsessive-Compulsive Disorder Using Adjunctive OlanzapineThe Journal of Clinical Psychiatry, 2004
- Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorderEuropean Neuropsychopharmacology, 1996
- Fluvoxamine Versus Clomipramine for Obsessive-Compulsive DisorderJournal of Clinical Psychopharmacology, 1996